Revolution Medicines
Yahoo Finance • 5 days ago
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting
REDWOOD CITY, Calif., April 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced new clinical... Full story
Yahoo Finance • 24 days ago
Barbara Weber, M.D., Elected to ITM Supervisory Board
Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. Th... Full story
Yahoo Finance • last month
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and... Full story
Yahoo Finance • last month
Revolution Medicines to Participate in April 2025 Investor Conferences
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.... Full story
Yahoo Finance • last month
Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy?
We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Revolution Medicines, Inc. (NASDAQ:RVMD) stands against the other best mid cap biotech stocks to buy. Is the... Full story
Yahoo Finance • 2 months ago
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it... Full story
Yahoo Finance • 3 months ago
Why Revolution Medicines, Inc. (RVMD) Is Among the Best Healthcare Stocks To Buy According to Analysts
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts.In this article, we are going to take a look at where Revolution Medicines, Inc. (NASDAQ:RVMD) stands against the other healthcare stocks. McKinsey... Full story
Yahoo Finance • 3 months ago
Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.... Full story
Yahoo Finance • 3 months ago
Is Revolution Medicines, Inc. (RVMD) the Best Russell 2000 Stock to Invest in According to Analysts?
We recently compiled a list of the 10 Best Russell 2000 Stocks to Invest in According to Analysts.In this article, we are going to take a look at where Revolution Medicines, Inc. (NASDAQ:RVMD) stands against other best Russell 2000 stocks... Full story
Yahoo Finance • 10 months ago
Insider Sale: COO Margaret Horn Sells Shares of Revolution Medicines Inc (RVMD)
On June 17, 2024, Margaret Horn, Chief Operating Officer of Revolution Medicines Inc (NASDAQ:RVMD), executed a sale of 4,415 shares of the company. According to the SEC Filing, the transaction was carried out at a stock price of $37.39 per... Full story
Yahoo Finance • last year
Revolution Medicines to Participate in Upcoming Investor Conferences
Revolution Medicines, Inc. REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that M... Full story
Yahoo Finance • last year
Revolution Medicines Completes Acquisition of EQRx
Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning, M.D., Joins Revolution Medicines' Boar... Full story
Yahoo Finance • last year
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. (Nasdaq: EQR... Full story
Yahoo Finance • last year
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to close later this month Revolution Medic... Full story
Yahoo Finance • 2 years ago
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.
REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy a... Full story
Yahoo Finance • 2 years ago
Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236
REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced promising anti-tumor and safety... Full story
Yahoo Finance • 2 years ago
Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting
Clinical dose escalation data for RMC-6236, a RASMULTI(ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary evidence of anti-tumor activity across multiple RAS mutations First clinical data presentation... Full story
Yahoo Finance • 2 years ago
Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast
Interim Data to be Presented for RMC-6236 (RASMULTI(ON) Inhibitor) and RMC-6291 (RASG12C(ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m. Eastern REDWOOD CITY, Calif., Oct. 04,... Full story
Yahoo Finance • 2 years ago
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor
KRASG12D(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring the KRASG12D mutation, the most common driver of RAS-addicted human cancers REDWOOD CITY, Calif., Sept. 19, 2023 (G... Full story
Yahoo Finance • 2 years ago
Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
Science Report on KRASG12C(ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasda... Full story
